MIM
TBIO

MetLife Investment Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

MetLife Investment Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,204
Closed -$667K – 2593
2021
Q2 		$667K Hold
24,204
– – 0.01% 1406
2021
Q1 		$399K Sell
24,204
-5,444
-18% -$124K ﹤0.01% 1654
2020
Q4 		$546K Hold
29,648
– – 0.01% 1449
2020
Q3 		$404K Buy
29,648
+6,859
+30% +$106K ﹤0.01% 1482
2020
Q2 		$408K Buy
22,789
+6,603
+41% +$99.6K ﹤0.01% 1493
2020
Q1 		$161K Hold
16,186
– – ﹤0.01% 1808
2019
Q4 		$132K Hold
16,186
– – ﹤0.01% 2190
2019
Q3 		$160K Hold
16,186
– – ﹤0.01% 2066
2019
Q2 		$204K Hold
16,186
– – ﹤0.01% 2012
2019
Q1 		$165K Buy
+16,186
New +$124K ﹤0.01% 2077

MetLife Investment Management's TBIO Position: Q3 2021 in Review

MetLife Investment Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 24,204 shares — an estimated $667K sold.

MetLife Investment Management first reported a position in TBIO in Q1 2019 and held it in 10 quarters. The position peaked at $667K in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • MetLife Investment Management reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 24,204 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $667K.
  • MetLife Investment Management first reported a position in Translate Bio, Inc. Common Stock in Q1 2019 and held it in 10 quarters.
  • MetLife Investment Management's Translate Bio, Inc. Common Stock position peaked at $667K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.